The overwhelming majority of GlaxoSmithKline shareholders on Thursday approved the proposed transaction with Novartis.
The U.S. Senate Special Committee on Aging unveiled a new bipartisan report earlier this week that focuses on ways to increase the use of generic drugs within the Medicare Part D program.
McKesson Specialty Health on Wednesday announced that its Reimbursement, Access & Safety Services Solution Center has earned certification by BenchmarkPortal as a Center of Excellence for the sixth consecutive year.
The American Pharmacists Association is reminding the 250 million people who visit the pharmacy each week to utilize their relationship with their neighborhood pharmacist to meet their health care and information needs during the cold and flu season.
Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.
The Food and Drug Administration on Wednesday approved Xtoro (finafloxacin otic suspension), a new drug that's used to treat acute otitis externa, commonly known as swimmer's ear.
Ipsen Biopharmaceuticals on Tuesday announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors.
To date, the Food and Drug Administration's Center for Drug Evaluation and Research has approved 35 novel new drugs in 2014, compared to 27 in 2013.
The Generic Pharmaceutical Association on Wednesday expressed concerns that the current structure of the Trans-Pacific Partnership agreement (TPP) will impede generic utilization.
McKesson Patient Relationship Solutions on Wednesday announced the successful launch of LoyaltyScript@Retail.